Orthofix Medical Inc.
NASDAQ:OFIXMedical - Devices
+$0.03 today
- Market cap
- $269.42M
- Beta
- 0.71
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.48
Volume 0.40M
Average 0.38M
OFIX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Orthofix Medical Inc.NASDAQ: OFIX
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q1 FY2026 cost of revenue of $57.16M fell 20.6% year over year, behind the -3.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 26.6% from the prior quarter. Over 3 fiscal years it compounded at +29.9% a year.
Context
- Cost of revenue amounted to 32.9% of revenue in FY2025, up 1.2 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -20.6% toward the trailing-twelve-month pace of -3.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 270.61M USD
- Year-over-year change
- +6.7%
- 4-year CAGR
- +23.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 270.61M | +6.7% |
| FY2024 | 2024-12-31 | 253.61M | -2.6% |
| FY2023 | 2023-12-31 | 260.37M | +110.7% |
| FY2022 | 2022-12-31 | 123.54M | +7.5% |
| FY2021 | 2021-12-31 | 114.91M | — |
Cost of Revenue vs competitors
How OFIX compares with its peers on the latest reported figures
- OFIX's LTM Mar 2026 cost of revenue of $255.74M is the 3rd highest of the 11 companies compared; the peer median is $48.44M.
- Its year-over-year change of -3.2% is the 8th highest of 11, against a peer median of +9.4%.
- Cost of revenue amounts to 31.0% of revenue for OFIX, versus a peer median of 51.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $569.8M | +3.9% | -1.3% | 66.4% | |
| LTM Mar 2026 | $368.3M | +18.2% | +6.7% | 51.4% | |
| LTM Mar 2026 | $255.74M | -3.2% | +29.9% | 31.0% | |
| LTM Mar 2026 | $146.39M | +62.5% | +68.6% | 35.0% | |
| LTM Mar 2026 | $100.69M | -21.2% | +11.3% | 62.9% | |
| LTM Mar 2026 | $52.28M | +55.2% | +15.2% | 50.8% | |
| LTM Mar 2026 | $44.6M | -34.2% | -11.1% | 51.7% | |
| LTM Mar 2026 | $42.1M | +14.9% | +37.7% | 20.4% | |
| LTM Mar 2026 | $26.01M | -49.9% | -41.6% | 1416.9% | |
| LTM Mar 2026 | $9.21M | -2.6% | -18.6% | 43.5% | |
| LTM Mar 2026 | $2.34M | +7090.5% | — | — | |
| Peer median (excluding OFIX) | $48.44M | +9.4% | +6.7% | 51.4% | |
Competitors are the stored peer set for OFIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 464.48M | 460.71M | 746.64M | 799.49M | 822.31M |
| Cost of Revenue | 114.91M | 123.54M | 260.37M | 253.61M | 270.61M |
| Gross Profit | 349.57M | 337.17M | 486.27M | 545.89M | 551.71M |
| Gross Margin | 75.3% | 73.2% | 65.1% | 68.3% | 67.1% |
| Research & Development | 49.62M | 49.07M | 80.23M | 73.64M | 57.11M |
| Selling, General & Admin | 290.67M | 308.78M | 530.4M | 532.53M | 456.39M |
| Operating Expenses | 357.88M | 350.44M | 625.38M | 630.5M | 620.18M |
| Depreciation & Amortization | 33.1M | 32.08M | 60.56M | 60.06M | 50.97M |
| EBITDA | 21.44M | 15.66M | (79.49M) | (34.18M) | (22.35M) |
| EBITDA Margin | 4.6% | 3.4% | -10.6% | -4.3% | -2.7% |
| Operating Income | (8.32M) | (13.27M) | (139.11M) | (84.62M) | (68.47M) |
| Operating Margin | -1.8% | -2.9% | -18.6% | -10.6% | -8.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.84M | 1.29M | 8.63M | 29.63M | 17.49M |
| Other Income / Expenses | (5.18M) | (4.44M) | (9.57M) | (39.26M) | (22.34M) |
| Income Before Tax | (13.5M) | (17.71M) | (148.68M) | (123.88M) | (90.81M) |
| Pre-Tax Margin | -2.9% | -3.8% | -19.9% | -15.5% | -11.0% |
| Income Tax Expense | 24.88M | 2.04M | 2.72M | 2.12M | 1.38M |
| Net Income | (38.38M) | (19.75M) | (151.4M) | (126M) | (92.19M) |
| Net Margin | -8.3% | -4.3% | -20.3% | -15.8% | -11.2% |
| EPS (Basic) | (1.95) | (0.98) | (4.12) | (3.30) | (2.28) |
| EPS (Diluted) | (1.95) | (0.98) | (4.12) | (3.30) | (2.28) |
| Weighted Avg Shares | 19.69M | 20.1M | 36.73M | 38.13M | 39.88M |
| Weighted Avg Shares (Diluted) | 19.69M | 20.1M | 36.73M | 38.13M | 39.88M |
Orthofix Medical Inc.
NASDAQ:OFIX
Intrinsic Alpha fair value
Locked
Current Price
$6.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.